The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 5, 2008, Pages 503-526

  Tunblad, Karin ^a   Lindbom, Lars ^a   McFadyen, Lynn ^b   Jonsson, E Niclas ^a   Marshall, Scott ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Covariates; Dofetilide; Modelling; NONMEM

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SOTALOL; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INDIVIDUALIZATION; KIDNEY CLEARANCE; MALE; MATHEMATICAL MODEL; NONLINEAR MIXED EFFECT MODELLING; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACOKINETICS; PHENETHYLAMINES; SULFONAMIDES; TACHYCARDIA; YOUNG ADULT;

EID: 57749114527     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-008-9099-z     Document Type: Article

References (28)

1. RH Falk A Pollak SN Singh T Friedrich 1997 Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter J Am Coll Cardiol 29 385 390 10.1016/S0735-1097(96) 00506-2
2. MJ Suttorp PE Polak A van 't Hof HS Rasmussen PH Dunselman JH Kingma 1992 Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter Am J Cardiol 69 417 419 10.1016/0002-9149(92)90247-V
3. BL Norgaard K Wachtell PD Christensen B Madsen JB Johansen EH Christiansen 1999 Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 137 1062 1069 10.1016/S0002-8703(99)70363-7
4. RH Falk JM Decara 2000 Dofetilide: a new pure class III antiarrhythmic agent Am Heart J 140 697 706 10.1067/mhj.2000.110457
5. M Gwilt JE Arrowsmith KJ Blackburn RA Burges PE Cross HW Dalrymple 1991 UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells J Pharmacol Exp Ther 256 318 324
6. F Le Coz C Funck-Brentano T Morell MM Ghadanfar P Jaillon 1995 Pharmacokinetic and pharmacodynamic modeling of the effects of oral and intravenous administrations of dofetilide on ventricular repolarization Clin Pharmacol Ther 57 533 542 10.1016/0009-9236(95)90038-1
7. M Sedgwick HS Rasmussen D Walker SM Cobbe 1991 Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug Br J Clin Pharmacol 31 515 519
8. JD Gemmill CA Howie PA Meredith AW Kelman HS Rasmussen WS Hillis 1991 A dose-ranging study of UK-68,798, a novel class III anti-arrhythmic agent, in normal volunteers Br J Clin Pharmacol 32 429 432
9. MJ Allen DJ Nichols SD Oliver 2000 The pharmacokinetics and pharmacodynamics of oral dofetilide after twice daily and three times daily dosing Br J Clin Pharmacol 50 247 253 10.1046/j.1365-2125.2000.00243.x
10. TC Tham BA MacLennan MT Burke DW Harron 1993 Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans J Cardiovasc Pharmacol 21 507 512
11. DA Smith HS Rasmussen DA Stopher DK Walker 1992 Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man Xenobiotica 22 709 717
12. DK Walker CT Alabaster GS Congrave MB Hargreaves R Hyland BC Jones 1996 Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data Drug Metab Dispos 24 447 455
13. LB Sheiner B Rosenberg VV Marathe 1977 Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J Pharmacokinet Biopharm 5 445 479 10.1007/BF01061728
14. EN Jonsson MO Karlsson 1998 Automated covariate model building within NONMEM Pharm Res 15 1463 1468 10.1023/A:1011970125687
15. L Sheiner J Wakefield 1999 Population modelling in drug development Stat Methods Med Res 8 183 193 10.1191/096228099672920676
16. J Ribbing EN Jonsson 2004 Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model J Pharmacokinet Pharmacodyn 31 109 134 10.1023/B:JOPA.0000034404.86036.72
17. L Lindbom P Pihlgren N Jonsson 2005 PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM Comput Methods Programs Biomed 79 241 257 10.1016/j.cmpb.2005.04.005
18. DK Walker GW Aherne JE Arrowsmith PE Cross B Kaye DA Smith 1991 Measurement of the class III antidysrhythmic drug, UK-68,798, in plasma by radioimmunoassay J Pharm Biomed Anal 9 141 149 10.1016/0731-7085(91)80137-X
19. Beal SL, Sheiner LS (1994) NONMEM user's guide. University of California at San Fransisco, NONMEM Project Group San Fransisco
20. EN Jonsson MO Karlsson 1999 Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 51 64 10.1016/S0169-2607(98)00067-4
21. DW Cockcroft MH Gault 1976 Prediction of creatinine clearance from serum creatinine Nephron 16 31 41 10.1159/000130554
22. Carroll RJ, Ruppert D (1988) Transformation and weighting in regression. Chapman & Hall, New York
23. PO Maitre M Buhrer D Thomson DR Stanski 1991 A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam J Pharmacokinet Biopharm 19 377 384 10.1007/BF01061662
24. JW Mandema D Verotta LB Sheiner 1992 Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects J Pharmacokinet Biopharm 20 511 528 10.1007/BF01061469
25. KG Kowalski MM Hutmacher 2001 Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test J Pharmacokinet Pharmacodyn 28 253 275 10.1023/A:1011579109640
26. U Wahlby EN Jonsson MO Karlsson 2002 Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis AAPS PharmSci 4 E27 10.1208/ps040427
27. S Abel DJ Nichols CJ Brearley MD Eve 2000 Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide Br J Clin Pharmacol 49 64 71 10.1046/j.1365-2125.2000.00114.x
28. ProductInformation (1999) Tikosyn [(TM)] dofetilide. Pfizer Inc., New York